Skip to main content
PACB
NASDAQ Industrial Applications And Services

Shareholders to Vote on 16M Share Equity Plan Increase with 26% Overhang

Analysis by Arik Shkolnikov
Sentiment info
Negative
Importance info
8
Price
$1.21
Mkt Cap
$378.934M
52W Low
$0.851
52W High
$2.73
Market data snapshot near publication time

summarizeSummary

Pacific Biosciences is seeking shareholder approval for a 16 million share increase in its equity incentive plan, which would result in a total equity overhang of 26.2% of outstanding shares, signaling significant potential dilution.


check_boxKey Events

  • Proposed Equity Plan Increase

    The company is seeking shareholder approval to add 16 million shares to its 2020 Equity Incentive Plan, bringing the total available shares to approximately 41.7 million (25.7M existing + 16M requested).

  • Significant Potential Dilution

    The total equity overhang, which includes outstanding options, RSUs, and the newly requested 16 million shares, represents 26.2% of the company's shares outstanding. This indicates substantial potential dilution for existing shareholders.

  • Stockholder Engagement and Compensation Changes

    The company engaged with stockholders regarding 'Say-on-Pay' feedback, leading to enhanced disclosure and the reintroduction of stock options into the long-term incentive program, which are viewed as performance-based.

  • Underwater Options Context

    A significant portion of outstanding options are currently underwater; for example, 64% would be underwater at a $1.50 share price, compared to the current stock price of $1.21. This context underscores the company's need for new equity incentives to motivate employees.


auto_awesomeAnalysis

This filing provides detailed justification and quantitative impact for the proposed 16 million share increase in the equity incentive plan, which was previously announced. The most significant new detail is the total equity overhang, including the requested shares, which stands at 26.2% of outstanding shares. This level of potential dilution is substantial and could significantly impact existing shareholder value. The company highlights the need for these shares to attract and retain talent in a competitive industry, especially given that a large portion of existing stock options are currently underwater due to the low stock price.

At the time of this filing, PACB was trading at $1.21 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $378.9M. The 52-week trading range was $0.85 to $2.73. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed PACB - Latest Insights

PACB
May 22, 2026, 4:50 PM EDT
Filing Type: DEFA14A
Importance Score:
8
PACB
May 08, 2026, 5:27 PM EDT
Filing Type: 10-Q
Importance Score:
7
PACB
May 07, 2026, 5:16 PM EDT
Source: Reuters
Importance Score:
8
PACB
May 07, 2026, 4:14 PM EDT
Filing Type: 8-K
Importance Score:
8
PACB
Apr 23, 2026, 4:40 PM EDT
Filing Type: DEF 14A
Importance Score:
8
PACB
Apr 21, 2026, 9:05 AM EDT
Source: GlobeNewswire
Importance Score:
7
PACB
Apr 15, 2026, 4:06 PM EDT
Source: Wiseek News
Importance Score:
7
PACB
Apr 15, 2026, 9:05 AM EDT
Source: GlobeNewswire
Importance Score:
8
PACB
Mar 06, 2026, 4:06 PM EST
Filing Type: 8-K
Importance Score:
8
PACB
Mar 05, 2026, 8:34 AM EST
Filing Type: 8-K
Importance Score:
7